You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Developing a blood fatty acid-based algorithm as an early predictor of insulin resistance: Applying machine learning to harmonized data from prospective cohort studies
SBC: OMEGAQUANT ANALYTICS, LLC. Topic: 200Project Summary Metabolic diseases, such as Metabolic Syndrome (MetSyn) and type 2 diabetes (T2DM) affect ~37% and ~10% of Americans, respectively, with a substantial impact on the health, quality of life and financial security of these individuals. Without the means to identify high risk individuals conveniently and cheaply, many will find care too little and too late: more than 80% of individual ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Renal Therapeutic Angiogenesis Using the Novel Biologic ELP-VEGF
SBC: LEFLORE TECHNOLOGIES LLC Topic: 400Abstract.Chronic kidney disease (CKD) is a progressive disorder affecting almost 14% of the general population, and this disease has shown a relentless growth over the past 2 decades. Patients with CKD have higher rates of hospitalization, greater mortality, shorter life expectancy, and their healthcare costs are up to 5 times more expensive than non-CKD patients. Thus, treatments to slow, halt, o ...
STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health -
Advancing a Candidate Human Polyclonal Anti-Thymocyte Globulin Product Produced in Transchromosomal Bovine for Transplant Induction/Acute Rejection and T1D Therapy
SBC: SAB Biotherapeutics, Inc. Topic: NIAIDProject Summary Abstract Currently available anti thymocyte globulinATGproducts are polyclonal animal antibodiesATGAMequine polyclonal ATGThymoglobulinrabbit polyclonal ATGand have found broad use as immune tolerizing agentsparticularly for induction therapy in a majority of tissue transplantsfor acute transplant rejectionand as treatment for graft vshost disease following bone marrow transplantsE ...
SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Improving treatment options and outcomes in fungal keratitis
SBC: TranZ Biosciences LLC Topic: NABSTRACT Fungal keratitisprimarily caused by CandidaFusariumor Aspergillus speciesis a leading cause of blindness among corneal diseasesAmphotericin BAmBremains the gold standard in the treatment of Candida keratitis and is also the fallback option for other corneal fungal infectionsAlthough widely used off label in ocular infectionsophthalmic AmB formulations are not available commerciallyThe com ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Development of a Process for GMP Production of Natural THC and CBD
SBC: ElSohly Laboratories, Incorporated Topic: R41Development Process for Production of Natural THC and CBD AbstractTetrahydrocannabinolTHCand cannabidiolCBDare two major constituents of the cannabis plant that have pharmacological properties with potential therapeutic value in several disease conditionsWhileTHC has already been in use clinically for two indicationsnausea and vomiting in cancer patients receiving chemotherapy and appetite stimula ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Advancing a Candidate Human Polyclonal Anti-Thymocyte Globulin Product Produced in Transchromosomal Bovine for Transplant Induction/Acute Rejection and T1D Therapy
SBC: SAB Biotherapeutics, Inc. Topic: NIAIDCurrently available anti-thymocyte globulin (ATG) products are polyclonal animal antibodies (ATGAM – equine polyclonal ATG, Thymoglobulin – rabbit polyclonal ATG) and have found broad use as immune tolerizing agents, particularly for induction therapy in a majority of tissue transplants, for acute transplant rejection, and as treatment for graft vs. host disease following bone marrow transplan ...
SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
An Opioid/Cannabinoid Analgesic that Boosts Pain Relief and Blocks Opiate Reward
SBC: ElSohly Laboratories, Incorporated Topic: NIDAProject Summary Abuse of prescription opioids and fatalities related to their misuse have increased sharply in recent yearsmaking the development of pain medications with reduced abuse potential a major public health priorityWhen combinedopioids and cannabinoidCBreceptor agonists show analgesic effects appear to be at least additive in a number of pain modelsCannabidiolCBDalthough much less psycho ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Multi-release drug-coated balloons for the treatment of peripheral artery disease with long, diffuse, and multiple lesions
SBC: Tailored Medical Devices Inc. Topic: NHLBIProject Summary Abstract Peripheral artery diseasePADaffects overmillion people worldwide and can result in life threating complicationsCurrentlydrug coated balloonsDCBsare used to treat lesions in the peripheral arteriesHowevercommercially available DCBs are designed to treat only a single blockage siteIn PAD patientscomplex lesions involving longdiffuseand or multiple blockages are often found r ...
SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
A Preclinical Trial of Therapeutic Angiogenesis Plus Angioplasty and Stenting for Renal Vascular Disease
SBC: LEFLORE TECHNOLOGIES LLC Topic: 400Abstract Chronic kidney disease CKD is a progressive disorder affecting almost of the general population and this disease has shown a relentless growth over the past decades Patients with CKD have higher rates of hospitalization greater mortality shorter life expectancy and their healthcare costs are up to times more expensive than non CKD patients Thus treatments to slow halt ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Development of a STAT2 knock-out hamster model for wild-type filovirus infections
SBC: Auratus Bio LLC Topic: 200DESCRIPTION provided by applicant Golden Syrian hamsters offer certain advantages over the use of other rodents in the study of a number of human diseases In the context of cancer research the histological and cytogenetic changes in the development of pancreatic cancers are similar in humans and hamsters but not in mice Hamsters are also the model species of choice for studying oncolytic ad ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health